MCID: OCL009
MIFTS: 59

Ocular Cancer malady

Categories: Neuronal diseases, Cancer diseases, Eye diseases

Aliases & Classifications for Ocular Cancer

Aliases & Descriptions for Ocular Cancer:

Name: Ocular Cancer 12 14
Eye Carcinoma 12 14 69
Eye Neoplasms 42 69
Eye Cancer 52 41
Malignant Eye Neoplasm 12
Neoplasm of Eye Proper 12
Malignant Tumor of Eye 69
Carcinoma of Eye 12
Ocular Carcinoma 12
Neoplasm of Eye 12
Eye Neoplasm 12
Ocular Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2174 DOID:295
ICD9CM 35 190.8
MeSH 42 D005134
NCIt 47 C3030 C6079

Summaries for Ocular Cancer

MedlinePlus : 41 cancer of the eye is uncommon. it can affect the outer parts of the eye, such as the eyelid, which are made up of muscles, skin and nerves. if the cancer starts inside the eyeball it's called intraocular cancer. the most common intraocular cancers in adults are melanoma and lymphoma. the most common eye cancer in children is retinoblastoma, which starts in the cells of the retina. cancer can also spread to the eye from other parts of the body. treatment for eye cancer varies by the type and by how advanced it is. it may include surgery, radiation therapy, freezing or heat therapy, or laser therapy.

MalaCards based summary : Ocular Cancer, also known as eye carcinoma, is related to ocular melanoma and encephalocraniocutaneous lipomatosis, and has symptoms including eye manifestations An important gene associated with Ocular Cancer is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Ranibizumab and Acarbose have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Disease Ontology : 12 An ocular cancer that has material basis in abnormally proliferating cells, derives from epithelial cells and arises_from the tissues that cover structures located in the eye.

Wikipedia : 71 Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer).... more...

Related Diseases for Ocular Cancer

Diseases related to Ocular Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 119)
id Related Disease Score Top Affiliating Genes
1 ocular melanoma 31.1 CCND1 CDKN1A CDKN2A TP53
2 encephalocraniocutaneous lipomatosis 10.6
3 intraocular lymphoma 10.6
4 osteomyelitis 10.3 CDK4 MDM2 RB1
5 extraosseous osteosarcoma 10.3 CDK4 MDM2 MYC
6 rommen mueller sybert syndrome 10.3 CDK4 MDM2 TP53
7 clear cell adenofibroma 10.3 CDKN2A TP53
8 intraorbital meningioma 10.3 MDM2 PLG TP53
9 breast mucoepidermoid carcinoma 10.3 MYC POU5F1 SOX2
10 aortic aneurysm 10.3 CDK4 CDKN2A MDM2
11 skeletal tuberculosis 10.3 CCND1 CDKN2A
12 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
13 endometrial disease 10.3 BRCA2 CDK4 CDKN2A
14 brain stem angioblastoma 10.3 CDK4 MDM2 TP53
15 fallopian tube carcinosarcoma 10.3 BRCA2 MYC TP53
16 extranodal nasal nk/t cell lymphoma 10.3 CDK4 CDKN2A RB1
17 enchondromatosis dwarfism deafness 10.3 CDK4 MDM2 TP53
18 villoglandular endometrial endometrioid adenocarcinoma 10.3 BRCA2 CCND1 TP53
19 endometrial squamous cell carcinoma 10.3 CDKN2A MDM2 TP53
20 acute mountain sickness 10.3 CDKN1A MDM2 TP53
21 liposarcoma of the ovary 10.3 CDK4 CDKN2A MDM2
22 scarlet fever 10.3 CDKN1A MDM2 TP53
23 paraphimosis 10.3 BRCA2 CDKN2A TP53
24 stickler syndrome, type i 10.3 CDK4 MDM2 TP53
25 13q12.3 microdeletion syndrome 10.3 CCND1 CDKN1A CDKN2A
26 mycobacterium kansasii 10.3 BRCA2 CCND1 TP53
27 apocrine sweat gland neoplasm 10.3 CDK4 CDKN2A MDM2 RB1
28 toxic megacolon 10.3 CDKN1A MDM2 TP53
29 ossifying fibromyxoid tumor 10.3 CDK4 CDKN2A TP53
30 papillary transitional carcinoma 10.3 CCND1 RB1 TP53
31 facial hemiatrophy 10.3 BRCA2 CDKN2A IL2
32 pulmonary immaturity 10.3 CDK4 MDM2 TP53
33 oro-mandibular-limb hypogenesis syndrome 10.2 CCND1 CDKN2A TP53
34 multifocal osteogenic sarcoma 10.2 CDK4 CDKN2A MDM2 MYC
35 brain stem medulloblastoma 10.2 CCND1 CDKN2A TP53
36 pyomyositis 10.2 BRCA2 CDKN2A TP53
37 hurst hallam hockey syndrome 10.2 CDK2 CDK4 CDKN1A
38 acute allergic sanguinous otitis media 10.2 CCND1 CDKN1A IL2
39 nodular cutaneous amyloidosis 10.2 CDKN2A SOX2 TP53
40 anal neuroendocrine tumor 10.2 CCND1 CDK6 CDKN2A
41 episodic ataxia 10.2 CCND1 CDK4 CDKN2A MDM2
42 toxascariasis 10.2 MYC POU5F1 SOX2 TP53
43 gestational choriocarcinoma 10.2 CDK4 MDM2 TP53
44 theileriasis 10.2 CCND1 IL2 MYC
45 advanced sleep phase syndrome 10.2 CCND1 CDKN2A TP53
46 house allergic alveolitis 10.2 CDK4 CDKN2A MDM2 TP53
47 interstitial lung disease 10.2 CDK4 CDKN2A MDM2 TP53
48 vascular myelopathy 10.2 CDKN2A MDM2 SOX2 TP53
49 connective tissue benign neoplasm 10.2 CCND1 CDKN2A TP53
50 anterior foramen magnum meningioma 10.2 IL2 MYC TP53

Graphical network of the top 20 diseases related to Ocular Cancer:



Diseases related to Ocular Cancer

Symptoms & Phenotypes for Ocular Cancer

UMLS symptoms related to Ocular Cancer:


eye manifestations

GenomeRNAi Phenotypes related to Ocular Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.36 MDM2 CDK2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.36 CDK2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.36 CCND1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.36 CDK2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.36 MDM2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.36 MDM2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.36 CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.36 MDM2 CDK2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.36 CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.36 CCND1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.36 MDM2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.36 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.36 MYC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.36 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.36 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.36 CCND1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.36 MYC
18 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.36 CCND1 MDM2 MYC CDK2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.36 CCND1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.36 CDK2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.36 MDM2 CDK2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.36 CDK2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.36 CDK2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.36 MDM2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.36 MYC
26 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.36 CDK2
27 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.13 BRCA2 CDK2 CDKN1A CDKN2A IL2 RB1
28 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.13 BRCA2 CCND1 CDK2 CDKN1A CDKN2A IL2
29 Decreased viability GR00221-A-1 10.1 CDK6 CDKN2A MYC RBL1 RBL2 SOX2
30 Decreased viability GR00221-A-2 10.1 CDK6 RBL1
31 Decreased viability GR00221-A-3 10.1 CDKN2A MYC
32 Decreased viability GR00221-A-4 10.1 CDK6 CDKN2A SOX2
33 Decreased viability GR00301-A 10.1 CDK6
34 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 BRCA2 CDK2 CDK4 CDK6 RBL1

MGI Mouse Phenotypes related to Ocular Cancer:

44 (show all 27)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.6 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDK6
2 endocrine/exocrine gland MP:0005379 10.55 CDK2 CDK4 CDK6 CDKN1A CDKN2A E2F4
3 cardiovascular system MP:0005385 10.53 CDKN1A CDKN2A COL4A2 E2F4 IL2 MDM2
4 hematopoietic system MP:0005397 10.53 COL4A2 E2F4 IL2 MDM2 MYC PLG
5 growth/size/body region MP:0005378 10.52 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
6 homeostasis/metabolism MP:0005376 10.5 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDKN1A
7 digestive/alimentary MP:0005381 10.49 PLG POU5F1 RB1 RBL1 SOX2 TP53
8 immune system MP:0005387 10.49 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDK6
9 mortality/aging MP:0010768 10.49 RBL1 RBL2 SOX2 TP53 CCND1 CDK2
10 behavior/neurological MP:0005386 10.48 BRCA2 CCND1 CDK4 CDKN1A CDKN2A E2F4
11 embryo MP:0005380 10.48 BRCA2 CDK2 CDK4 CDK6 CDKN1A CDKN2A
12 integument MP:0010771 10.48 TP53 CDK2 CDK4 CDKN1A CDKN2A E2F4
13 neoplasm MP:0002006 10.41 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
14 liver/biliary system MP:0005370 10.37 ABCG2 CDK2 CDK4 CDK6 CDKN1A CDKN2A
15 nervous system MP:0003631 10.36 COL4A2 MDM2 MYC PLG POU5F1 RB1
16 craniofacial MP:0005382 10.32 CCND1 CDKN1A E2F4 MDM2 MYC RB1
17 muscle MP:0005369 10.27 CDK2 CDK4 CDK6 CDKN1A CDKN2A MDM2
18 normal MP:0002873 10.22 MYC POU5F1 RB1 RBL1 RBL2 SOX2
19 reproductive system MP:0005389 10.21 POU5F1 RB1 RBL1 RBL2 SOX2 TP53
20 hearing/vestibular/ear MP:0005377 10.19 CDKN1A E2F4 MYC RB1 RBL1 RBL2
21 no phenotypic analysis MP:0003012 10.17 MDM2 MYC RB1 RBL1 RBL2 SOX2
22 limbs/digits/tail MP:0005371 10.14 TP53 BRCA2 CDKN1A MDM2 MYC RB1
23 renal/urinary system MP:0005367 9.97 ABCG2 CDK4 CDKN1A MDM2 PLG RB1
24 pigmentation MP:0001186 9.91 MYC RB1 SOX2 TP53 CDK4 CDKN2A
25 respiratory system MP:0005388 9.9 CCND1 CDKN1A CDKN2A E2F4 IL2 PLG
26 skeleton MP:0005390 9.73 CCND1 CDKN1A CDKN2A E2F4 MDM2 MYC
27 vision/eye MP:0005391 9.44 RB1 RBL1 RBL2 SOX2 TP53 CCND1

Drugs & Therapeutics for Ocular Cancer

Drugs for Ocular Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1223)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 347396-82-1 459903
2
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
3
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 111025-46-8 4829
4
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 7439-89-6 23925
5
Colchicine Approved Phase 4 64-86-8 6167 2833
6
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 1 99210-65-8, 215647-85-1
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
8
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
9
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
10
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
11
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
12
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
13
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6 772 46507594
14
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 216974-75-3
15
Mannitol Approved, Investigational Phase 4,Phase 1,Phase 2 69-65-8 453 6251
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
17
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
18
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
19
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
20
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
21
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
22
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
23
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
24
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
25
Indinavir Approved Phase 4,Phase 2 150378-17-9 5362440
26
Zinc Approved Phase 4,Phase 3,Early Phase 1 7440-66-6 32051 23994
27
Amphotericin B Approved, Investigational Phase 4,Phase 2 1397-89-3 14956 5280965
28
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 299-42-3 9294
29
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 90-82-4 7028
30
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
31
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
32
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
33
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
34
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
35
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
36
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 185243-69-0
37
Hydroxychloroquine Approved Phase 4,Phase 1,Phase 2,Early Phase 1 118-42-3 3652
38
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216503-57-0
39
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
40
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
41
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1 53608-75-6
42
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
43
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
44
Memantine Approved, Investigational Phase 4,Phase 3 19982-08-2 4054
45
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
46
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
47
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 51-43-4 5816
48
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53714-56-0 3911 657181
49
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-83-0 5994
50
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563

Interventional clinical trials:

(show top 50) (show all 4952)
id Name Status NCT ID Phase
1 Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Unknown status NCT00172965 Phase 4
2 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
3 Lymphoma in the Orbit Unknown status NCT01302912 Phase 4
4 The Hysteroscopic Morcellator (HM). Unknown status NCT01537822 Phase 4
5 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4
6 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4
7 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Unknown status NCT00920023 Phase 4
8 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
9 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4
10 Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. Unknown status NCT00179413 Phase 4
11 Pioglitazone Vs Placebo in Combination With Niacin Extended Release on Low HDL Unknown status NCT00300365 Phase 4
12 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4
13 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4
14 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
15 Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients Completed NCT01641458 Phase 4
16 Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung Completed NCT00747773 Phase 4
17 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4
18 LUCAS (Lucentis Compared to Avastin Study) Completed NCT01127360 Phase 4
19 Vascular Endothelial Growth Factor in Stage V ROP Completed NCT00500396 Phase 4
20 Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT00504959 Phase 4
21 Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD) Completed NCT02142296 Phase 4
22 Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy Completed NCT02246023 Phase 4
23 Pediatric Zylet Safety and Efficacy Study Completed NCT00420628 Phase 4
24 Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Completed NCT01181570 Phase 4
25 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4
26 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
27 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
28 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4
29 Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results Completed NCT00858104 Phase 4
30 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4
31 Comparison Colon Capsule Endoscopy vs Optical Colonoscopy for Colorectal Cancer Screening in Familiar-Risk Population Completed NCT01557101 Phase 4
32 An Alternative to A Fixed Schedule In Management Of Prostate Cancer Completed NCT01056562 Phase 4
33 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4
34 Study to Monitor the Effects of Androgen Suppression Treatment on the Heart Completed NCT01230905 Phase 4
35 Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain Completed NCT00378937 Phase 4
36 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
37 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Completed NCT01861717 Phase 4
38 Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC Completed NCT01203917 Phase 4
39 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4
40 A Study of Infliximab for Treatment Resistant Major Depression Completed NCT00463580 Phase 4
41 Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
42 Pediatric Hypothalamic Obesity Completed NCT00076362 Phase 4
43 INVEST: INternational VErapamil SR Trandolapril STudy Completed NCT00133692 Phase 4
44 Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC) Completed NCT00581425 Phase 4
45 Pathophysiology of Post Amputation Pain Completed NCT01632709 Phase 4
46 Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia Completed NCT00002386 Phase 4
47 Fibroids in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4
48 PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia Completed NCT00362544 Phase 4
49 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4
50 Preoperative Brimonidine on IOP of Patients Undergoing RALP Recruiting NCT02818816 Phase 4

Search NIH Clinical Center for Ocular Cancer

Cochrane evidence based reviews: eye neoplasms

Genetic Tests for Ocular Cancer

Anatomical Context for Ocular Cancer

MalaCards organs/tissues related to Ocular Cancer:

39
Eye, Skin, Lung, Kidney, Breast, Thyroid, Prostate

The Foundational Model of Anatomy Ontology organs/tissues related to Ocular Cancer:

18
The Eye

Publications for Ocular Cancer

Articles related to Ocular Cancer:

(show all 15)
id Title Authors Year
1
Views on ocular cancer in Arabo-Islamic medicine and the leading influence of the ancient Greek medicine. ( 27061559 )
2016
2
TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications. ( 25834817 )
2015
3
The pathology of ocular cancer. ( 23154492 )
2013
4
Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells. ( 23441619 )
2013
5
Chemical inhibition of fatty acid synthase: molecular docking analysis and biochemical validation in ocular cancer cells. ( 23181152 )
2010
6
Id2 deficiency promotes metastasis in a mouse model of ocular cancer. ( 20127274 )
2010
7
Differential regulation of Dlg1, Scrib, and Lgl1 expression in a transgenic mouse model of ocular cancer. ( 19098995 )
2008
8
A gene transfer comparative study of HSA-conjugated antiangiogenic factors in a transgenic mouse model of metastatic ocular cancer. ( 17082795 )
2007
9
Non-cancerous ophthalmic clues to non-ocular cancer. ( 12431692 )
2002
10
Non-ocular cancer in relatives of retinoblastoma patients. ( 2789942 )
1989
11
Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. ( 3356485 )
1988
12
Non-ocular cancer in hereditary retinoblastoma survivors and relatives. ( 3587888 )
1987
13
Non-ocular cancer in retinoblastoma survivors. ( 2837050 )
1987
14
Photodynamic therapy of human ocular cancer. ( 2956549 )
1987
15
Recent trends in the treatment of intra-ocular cancer. ( 13790869 )
1960

Variations for Ocular Cancer

Cosmic variations for Ocular Cancer:

9 (show all 38)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM889 RB1 eye,retina,retinoblastoma,NS c.2158A>T p.K720* 14
2 COSM890 RB1 eye,retina,retinoblastoma,NS c.409G>T p.E137* 14
3 COSM3724517 RB1 eye,retina,retinoblastoma,NS c.862-5T>G p.? 14
4 COSM895 RB1 eye,retina,retinoblastoma,NS c.1363C>T p.R455* 14
5 COSM1030 RB1 eye,retina,retinoblastoma,NS c.1961-1G>A p.? 14
6 COSM878 RB1 eye,retina,retinoblastoma,NS c.751C>T p.R251* 14
7 COSM891 RB1 eye,retina,retinoblastoma,NS c.958C>T p.R320* 14
8 COSM1636648 RB1 eye,retina,retinoblastoma,NS c.2106+2T>G p.? 14
9 COSM936 RB1 eye,retina,retinoblastoma,NS c.1183C>T p.Q395* 14
10 COSM888 RB1 eye,retina,retinoblastoma,NS c.1666C>T p.R556* 14
11 COSM882 RB1 eye,retina,retinoblastoma,NS c.2152G>A p.D718N 14
12 COSM876 RB1 eye,retina,retinoblastoma,NS c.160G>T p.E54* 14
13 COSM887 RB1 eye,retina,retinoblastoma,NS c.1654C>T p.R552* 14
14 COSM13117 RB1 eye,retina,retinoblastoma,NS c.2053C>T p.Q685* 14
15 COSM877 RB1 eye,retina,retinoblastoma,NS c.341C>A p.S114* 14
16 COSM1041 RB1 eye,retina,retinoblastoma,NS c.1049+1G>T p.? 14
17 COSM943 RB1 eye,retina,retinoblastoma,NS c.763C>T p.R255* 14
18 COSM1050 RB1 eye,retina,retinoblastoma,NS c.1421G>A p.S474N 14
19 COSM880 RB1 eye,retina,retinoblastoma,NS c.1333C>T p.R445* 14
20 COSM910 RB1 eye,retina,retinoblastoma,NS c.1467C>A p.C489* 14
21 COSM144722 RB1 eye,retina,retinoblastoma,NS c.265-2A>C p.? 14
22 COSM1026 RB1 eye,retina,retinoblastoma,NS c.2326-2A>C p.? 14
23 COSM1016 RB1 eye,retina,retinoblastoma,NS c.1960+1G>A p.? 14
24 COSM3724518 RB1 eye,retina,retinoblastoma,NS c.2520+4A>G p.? 14
25 COSM1015 RB1 eye,retina,retinoblastoma,NS c.1215+1G>A p.? 14
26 COSM1014 RB1 eye,retina,retinoblastoma,NS c.1216-2A>G p.? 14
27 COSM1040 RB1 eye,retina,retinoblastoma,NS c.1960+2T>C p.? 14
28 COSM938 RB1 eye,retina,retinoblastoma,NS c.967G>T p.E323* 14
29 COSM3724510 RB1 eye,retina,retinoblastoma,NS c.2527G>T p.E843* 14
30 COSM942 RB1 eye,retina,retinoblastoma,NS c.2063T>C p.L688P 14
31 COSM1013 RB1 eye,retina,retinoblastoma,NS c.1389+1G>C p.? 14
32 COSM903 RB1 eye,retina,retinoblastoma,NS c.1494T>A p.Y498* 14
33 COSM911 RB1 eye,retina,retinoblastoma,NS c.1166T>A p.L389* 14
34 COSM1047 RB1 eye,retina,retinoblastoma,NS c.982A>C p.N328H 14
35 COSM1017 RB1 eye,retina,retinoblastoma,NS c.380+1G>T p.? 14
36 COSM764 PIK3CA eye,retina,retinoblastoma,NS c.1634A>G p.E545G 14
37 COSM521 KRAS eye,retina,retinoblastoma,NS c.35G>A p.G12D 14
38 COSM520 KRAS eye,retina,retinoblastoma,NS c.35G>T p.G12V 14

Expression for Ocular Cancer

Search GEO for disease gene expression data for Ocular Cancer.

Pathways for Ocular Cancer

Pathways related to Ocular Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 99)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.28 CCND1 CDK2 CDK4 CDKN1A COL4A2 E2F4
2
Show member pathways
14.02 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
3
Show member pathways
13.86 BRCA2 CCND1 CDK2 CDK4 CDKN1A CDKN2A
4
Show member pathways
13.62 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
5
Show member pathways
13.28 CDK2 CDK4 CDK6 CDKN1A CDKN2A MDM2
6
Show member pathways
13.23 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
7
Show member pathways
13.13 CDK2 CDKN1A CDKN2A E2F4 MDM2 RBL1
8
Show member pathways
13.11 CCND1 CDK2 CDK4 CDK6 CDKN1A IL2
9
Show member pathways
12.96 CCND1 CDK2 CDK4 CDK6 IL2 PLG
10
Show member pathways
12.88 CDKN1A CDKN2A MDM2 MYC TP53
11
Show member pathways
12.88 BRCA2 CCND1 CDK2 CDK4 CDKN1A E2F4
12 12.85 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
13 12.78 CCND1 CDK2 CDK4 CDK6 CDKN1A COL4A2
14 12.72 CCND1 CDK6 CDKN1A CDKN2A MDM2 MYC
15 12.7 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
16
Show member pathways
12.7 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
17
Show member pathways
12.69 CDKN1A IL2 MYC PLG TP53
18 12.69 CCND1 CDK2 CDK4 CDK6 E2F4 MYC
19 12.68 CCND1 CDK4 CDKN1A CDKN2A IL2 MYC
20
Show member pathways
12.66 CCND1 MDM2 MYC RB1 TP53
21
Show member pathways
12.66 CCND1 MYC POU5F1 SOX2 TP53
22
Show member pathways
12.61 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
23 12.58 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
24
Show member pathways
12.55 CCND1 CDK2 CDK4 CDK6 RB1
25
Show member pathways
12.53 CCND1 CDKN1A MDM2 MYC TP53
26
Show member pathways
12.5 CCND1 CDKN1A MDM2 MYC TP53
27
Show member pathways
12.5 CCND1 CDK2 CDK4 CDKN1A E2F4 MDM2
28 12.49 CDK2 CDKN1A MDM2 MYC RB1 TP53
29
Show member pathways
12.45 CCND1 CDKN1A MDM2 MYC TP53
30 12.44 CCND1 CDKN1A MDM2 MYC TP53
31
Show member pathways
12.44 CCND1 CDK2 CDK4 CDKN1A E2F4 MDM2
32
Show member pathways
12.42 CDK2 CDKN1A RB1 TP53
33 12.41 BRCA2 CCND1 CDK2 CDK4 MDM2 MYC
34
Show member pathways
12.41 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
35
Show member pathways
12.4 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
36 12.34 CCND1 CDKN1A E2F4 MYC TP53
37 12.34 CCND1 CDK2 CDK4 CDKN1A CDKN2A MDM2
38 12.33 CCND1 CDKN1A E2F4 MYC RBL1 RBL2
39 12.32 CDKN1A MDM2 MYC TP53
40
Show member pathways
12.3 CCND1 CDKN1A IL2 MYC
41 12.27 CCND1 CDK2 CDK4 IL2 MYC RB1
42
Show member pathways
12.26 CCND1 CDK2 CDKN1A MDM2 RBL2
43 12.25 CCND1 CDKN1A CDKN2A MDM2 MYC RBL2
44 12.23 CDKN1A E2F4 RB1 RBL1 RBL2
45